- Home
- OCFT vs IPHA Comparison
OCFT vs IPHA Comparison
Compare OCFT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFT
- IPHA
- Stock Information
- Founded
- OCFT 2015
- IPHA 1999
- Country
- OCFT China
- IPHA France
- Employees
- OCFT N/A
- IPHA N/A
- Industry
- OCFT Computer Software: Programming Data Processing
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- OCFT Technology
- IPHA Health Care
- Exchange
- OCFT Nasdaq
- IPHA Nasdaq
- Market Cap
- OCFT 159.5M
- IPHA 160.1M
- IPO Year
- OCFT 2019
- IPHA 2019
- Fundamental
- Price
- OCFT $3.70
- IPHA $2.24
- Analyst Decision
- OCFT Strong Buy
- IPHA Strong Buy
- Analyst Count
- OCFT 1
- IPHA 1
- Target Price
- OCFT $7.00
- IPHA $11.50
- AVG Volume (30 Days)
- OCFT 54.9K
- IPHA 650.0K
- Earning Date
- OCFT 03-17-2025
- IPHA 03-20-2025
- Dividend Yield
- OCFT N/A
- IPHA N/A
- EPS Growth
- OCFT N/A
- IPHA N/A
- EPS
- OCFT 0.00
- IPHA N/A
- Revenue
- OCFT $407,825,504.00
- IPHA $36,202,722.00
- Revenue This Year
- OCFT N/A
- IPHA N/A
- Revenue Next Year
- OCFT N/A
- IPHA $93.37
- P/E Ratio
- OCFT $39.83
- IPHA N/A
- Revenue Growth
- OCFT N/A
- IPHA N/A
- 52 Week Low
- OCFT $0.87
- IPHA $1.29
- 52 Week High
- OCFT $4.98
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- OCFT 57.89
- IPHA 63.01
- Support Level
- OCFT $4.03
- IPHA $2.07
- Resistance Level
- OCFT $4.50
- IPHA $2.38
- Average True Range (ATR)
- OCFT 0.37
- IPHA 0.13
- MACD
- OCFT 0.07
- IPHA 0.04
- Stochastic Oscillator
- OCFT 52.53
- IPHA 78.79
About OCFT OneConnect Financial Technology Co. Ltd.
OneConnect Financial Technology Co Ltd is a provider of technology platforms. Its platform provides cloud-native technology solutions that integrate financial services with market technology. The company offers technology applications and technology-enabled business services to financial institutions in China. Its technology solutions cover multiple verticals in the financial services industry, including banking, insurance and asset management, across the full scope of their businesses from sales and marketing and risk management to customer services and operations, as well as technology infrastructures such as data management and cloud services. The firm operates in two segments namely Technology Solutions which is the key revenue driver and Virtual Bank Business.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.